ArticleDiscover oncology2025
Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling novel therapeutic targets for diffuse large B-cell lymphoma: a plasma multi-omics study.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundLymphoma is a common hematologic malignancy with limited treatment options. The research objective was to ascertain plasma proteins that could be targeted for lymphoma treatment.
methodsWe conducted proteome-wide mendelian randomization (PW-MR) analyses on blood proteins from the deCODE (N = 355,559) and Fenland (N = 10,708) studies. Protein-protein interaction (PPI), sensitivity analysis and external validation were used to identify potential drug targets. We analyzed enrichment analysis, single cell sequencing, drug prediction, molecular docking, mouse genome informatics (MGI), qRT-PCR and CCK-8 assays.
resultsPW-MR analyses predicted 37 proteins associated with lymphoma. Therein, 8 proteins, including APOBEC3G, TNFAIP6, LY75, MAPK3, SERPING1, CSF2RB, FCRL3, and LY9, interacted with known lymphoma drug targets. Through enrichment analysis, these 8 proteins were found to be linked to organism's response to stimuli and the proliferation of leukocytes. PheWAS identified LY75, SERPING1 and CSF2RB as associated with hematologic abnormalities and immune disorders. Single cell analysis revealed the expression enrichment of FCRL3 and LY9 in B cells. The affinity between 5 potential drug targets and predicted lymphoma drugs was identified by molecular docking, and the association of LY75, MAPK3, CSF2RB, LY9 with abnormalities in the hematopoietic system was confirmed in MGI. Finally, qRT-PCR showed that FCRL3 and LY9 mRNA levels were significantly down-regulated in diffuse large B-cell lymphoma (DLBCL) cells. In CCK-8 assay, predicted drugs amiodarone and chrysin inhibited DLBCL cell proliferation in dose-dependent and time-dependent manner.
conclusionsOur study identified 37 potential lymphoma drug targets, emphasizing FCRL3 and LY9 as valuable therapeutic candidates, and amiodarone and chrysin in clinical translational application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.